Welcome to our dedicated page for CureVac N.V. Ordinary Shares news (Ticker: CVAC), a resource for investors and traders seeking the latest updates and insights on CureVac N.V. Ordinary Shares stock.
CureVac N.V. (NASDAQ: CVAC) is a pioneering biopharmaceutical company based in Germany, known for its groundbreaking work in the field of messenger RNA (mRNA) technology. Founded in 2000 as a spin-off from the University of Tübingen, CureVac has developed a unique position as a leader in mRNA research and development. The company's core technology uses mRNA as a data carrier that instructs the human body to produce its own proteins capable of fighting a wide range of diseases, including cancer, infectious diseases, and rare genetic disorders.
CureVac's proprietary mRNA technology has a broad range of applications. In oncology, the company is developing both off-the-shelf and personalized cancer vaccines. Their off-the-shelf cancer vaccines target tumor antigens shared across different cancer types, while the personalized vaccines are tailored to individual patients based on their unique tumor profiles. CureVac has recently entered a collaboration with The University of Texas MD Anderson Cancer Center to further this mission.
In infectious disease, CureVac has partnered with pharmaceutical giant GSK to develop a suite of prophylactic vaccines. This includes second-generation COVID-19 vaccines and a promising seasonal influenza vaccine program. Recent Phase 2 interim data showed that CureVac's influenza vaccine candidates produce higher geometric mean titers against influenza A strains compared to licensed vaccines, though optimizations are ongoing for influenza B strains. Additionally, a new Phase 2 study has been initiated to further enhance the immune response against the relevant influenza B strain.
Financially, CureVac remains robust, with cash and cash equivalents amounting to €402.5 million at the end of 2023. The company's strategic initiatives, such as organizational redesign and partnerships, aim to extend this runway into the fourth quarter of 2025. As of late, CureVac has also achieved significant milestones in its clinical pipeline, which includes a move to Phase 2 studies for its H5N1 avian flu vaccine candidate and ongoing litigation to defend its intellectual property rights.
Overall, CureVac continues to push the boundaries of mRNA technology, with a deep clinical pipeline and strong collaborations to back its innovative discoveries. For more information, visit their official website at www.curevac.com.
CureVac N.V. (Nasdaq:CVAC) reported significant advancements in its vaccine development, including second-generation candidates for COVID-19 and influenza now in Phase 1 trials. The company is positioned to receive a €10 million milestone payment from GSK for starting its influenza clinical trial. CureVac's cash position is €658.2 million, down from €811.5 million, primarily due to wind-down costs of the CVnCoV vaccine program. Revenues surged 144% to €24.4 million, mainly attributed to collaborations with GSK, while operating loss decreased from €115.8 million to €15.3 million.
CureVac announced its fourth-quarter and full-year 2021 financial results, highlighting a strong cash position of €811.5 million. The company initiated several clinical studies for its second-generation mRNA vaccines targeting COVID-19 and influenza, collaborating with GSK. The CV2CoV candidate is in Phase 1 trials, with promising results from a bivalent vaccine approach. Revenues surged to €103 million, up 111%, driven by GSK collaborations. However, operating losses increased to €412.3 million.
CureVac N.V. (NASDAQ:CVAC) will announce its Q4 and full-year 2021 financial results on April 28, 2022. The event will include a conference call at 3 p.m. CET / 9 a.m. EST. Interested participants can access the call through designated numbers or via a live webcast on the company's website. CureVac specializes in mRNA technology for medical applications, with significant collaborations and a diversified clinical pipeline. The press release emphasizes forward-looking statements regarding future developments, emphasizing the inherent risks associated with such projections.
CureVac, in collaboration with GSK, announced promising preclinical results for a bivalent COVID-19 vaccine candidate targeting the Beta and Delta variants. The study revealed that this bivalent mRNA vaccine generated comparable neutralizing antibody levels to monovalent candidates while demonstrating significantly enhanced neutralization against the Omicron variant. Conducted on mice, the bivalent approach showed strong immune responses and reduced viral loads. This technology could pave the way for broader protection against evolving variants.
CureVac has entered a contract with the German government to ensure mRNA vaccine manufacturing capacity until 2029 in response to potential health emergencies. The agreement allows for the production of up to 80 million doses during public health crises. Following a two-year setup period, the federal government will pay an annual standby fee to keep the manufacturing capacity ready, thereby enhancing pandemic preparedness. This partnership emphasizes the significance of mRNA technology in swiftly addressing future infectious disease threats.
CureVac and GSK have initiated a Phase 1 dose-escalation study for their second-generation COVID-19 vaccine candidate CV2CoV in the U.S., with the first participant dosed. This trial is crucial to evaluate the candidate's safety and immune response, building on promising preclinical data that suggests better efficacy compared to the first-generation vaccine. The study aims to enroll 210 healthy adults, with results anticipated in the second half of 2022, marking a significant step in advancing mRNA vaccine technology.
CureVac N.V. (NASDAQ:CVAC) has launched CureVac RNA Printer GmbH, a wholly-owned subsidiary designed to enhance the development and operational capacity of The RNA Printer(R), an automated RNA vaccine and therapeutic manufacturing solution. This initiative aims to facilitate rapid access to mRNA technology, particularly in pandemic situations and personalized therapies. Dr. Markus Bergmann has been appointed General Manager, bringing extensive expertise in business development and a medical background. The announcement highlights CureVac's commitment to expanding its footprint in the mRNA market.
CureVac (NASDAQ: CVAC) has initiated a Phase 1 study for its seasonal influenza mRNA vaccine candidate CVSQIV, dosing the first participant in Panama. This vaccine, developed in partnership with GSK, employs a multivalent approach to target four different influenza strains using non-chemically modified mRNA. The study aims to enroll up to 240 healthy adults to assess the safety and immune response. The collaboration focuses on enhancing mRNA vaccine technologies for infectious diseases, building on the successful application during the COVID-19 pandemic.
CureVac N.V. (NASDAQ:CVAC) announced the resignation of Chief Technology Officer Dr. Mariola Fotin-Mleczek, effective January 31, 2022, after nearly 16 years with the company. She is transitioning to a family business in Poland. Dr. Igor Splawski, Chief Scientific Officer, will lead the continued development of CureVac's mRNA technology. The company's innovative mRNA platform has contributed significantly to medical advancements, including vaccines and therapies across various therapeutic areas. CureVac has a strong pipeline and is focused on leveraging its mRNA technology for future growth.
BERLIN, GERMANY / ACCESSWIRE / January 13, 2022 / dievini and the Federal Republic of Germany have amended their shareholders' agreement regarding CureVac N.V. (NASDAQ:CVAC). This update follows the succession planning for Dietmar Hopp's estate, resulting in dievini's ownership being transferred to the Hopp family. The agreement details shareholder voting behavior and board appointments. dievini plans to sell CureVac shares to finance restructuring, although no current sales to third parties are expected. dievini holds about 42% of CureVac's common shares.
FAQ
What is the current stock price of CureVac N.V. Ordinary Shares (CVAC)?
What is the market cap of CureVac N.V. Ordinary Shares (CVAC)?
What does CureVac N.V. do?
Where is CureVac headquartered?
Who are CureVac's notable partners?
What are CureVac's recent achievements in vaccine development?
How is CureVac financially positioned?
What is the role of mRNA in CureVac's technology?
What are CureVac's focus areas in oncology?
What are some challenges CureVac has faced?
What recent collaborations has CureVac entered into?
What is CureVac's latest financial result?
